Unigene Successfully Completes Phase I/II Clinical Study For Oral Calcitonin
Unigene Laboratories, Inc. (OTCBB: UGNE) has successfully completed the Phase I/II oral calcitonin clinical study that it initiated last month. This study, which achieved all of its planned objectives, primarily measured the ability of Unigene’s proprietary oral delivery technology to significantly reduce the levels of an established biochemical marker that correlates with bone loss. All of the twenty-two subjects who completed the study demonstrated a robust reduction in this marker.
More: continued here
Filed under: Bones on March 15th, 2008